Alcaraz, A <br/><br/>
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.  [electronic resource] 

 -  British journal of cancer  Jul 2013 
 - 121-30 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2013.272  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Alkaline Phosphatase--blood<br/>Biomarkers, Tumor--blood<br/>Bone Density Conservation Agents--therapeutic use<br/>Bone Neoplasms--drug therapy<br/>Bone Remodeling<br/>Bone and Bones--enzymology<br/>Carcinoma, Renal Cell--metabolism<br/>Collagen Type I--blood<br/>Diphosphonates--therapeutic use<br/>Disease Progression<br/>Female<br/>Humans<br/>Imidazoles--therapeutic use<br/>Kidney Neoplasms--metabolism<br/>Male<br/>Middle Aged<br/>Peptide Fragments--blood<br/>Procollagen--blood<br/>Prospective Studies<br/>Treatment Outcome<br/>Urinary Bladder--metabolism<br/>Urinary Bladder Neoplasms--metabolism<br/>Zoledronic Acid